Healthcare Industry News: Intravenous Immunoglobulin
News Release - January 30, 2006
Gammacan to Explore the Efficacy of IVIg sourced from Specific Population for the Treatment of Malignant Melanoma PatientsCompany is Entering Initial Process to Test the Efficacy of a Unique IVIg as a New and Advanced Malignant Melanoma Treatment Option
GIVAT SHMUEL, Israel--(HSMN NewsFeed)--Jan. 30, 2006--Gammacan International (OTC BB:GCAN ), a developer of immunotherapies for cancer and other diseases, today announced that it is considering an additional clinical trial to demonstrate clinical efficacy of hyperimmune Intravenous Immunoglobulin (IVIg), sourced from a specific population, for treating Melanoma, a common and serious skin cancer. The Company is presently in a Phase II clinical trial utilizing its GCAN - 101 for the treatment of metastatic melanoma, prostate and colon cancers.
Although melanoma accounts for only 4% of all skin cancers, it accounts for more than 70% of all skin cancer deaths and the patient population is steadily increasing. The Melanoma Research Foundation noted, "No significant advances in medical therapies (or survival) for patients with advanced melanoma have occurred in the past 30 years".
"We believe that the existing research results regarding the use of IVIG for treatment of Melanoma provide sufficient incentive to advance to a clinical stage the efficacy of IVIg sourced from a specific population for the treatment of Malignant Melanoma," stated Vered Caplan, CEO.
"Expanding our pipeline of IVIG-based therapies and targeting specific cancers where little therapeutic benefit has been seen is key to the Company's growth and to patients suffering from such devastating diseases," Caplan concluded.
Gammacan is focusing on the commercialization of a revolutionary anti-cancer immunotherapy that the Company believes will be proven to be effective in reducing the metastatic spread of a wide range of cancers. Gammacan's proposed treatment is based on IVIG, a safe, relatively non-toxic human plasma-based product, currently used to treat a variety of immune deficiencies and autoimmune diseases. It works by strengthening the patient's immune system. Many experts currently view immunotherapy as a future alternative to today's standard chemotherapy. Approximately twenty companies produce IVIG, and annual worldwide sales are currently in excess of 50 metric tones with an estimated value in excess of 1.5 billion USD. IVIG is commonly used to treat certain autoimmune diseases and blood disorders and to replace the antibodies in people who are unable to produce them. For more information about Gammacan visit www.gammacan.com or call the company's headquarters in Givat Shmuel, Israel at 972 3 5774475.
Safe Harbor Statement:
Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding: the commercialization of an anti-cancer immunotherapy and the Company developing the boosting of cancer patients' immune systems with IVIG into an effective treatment. Actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technology, inability to hire appropriate staff to develop the technology, unforeseen technical difficulties in developing the technology, inability to obtain regulatory approval for human use, competitors' therapies proving more effective, cheaper or otherwise preferable for consumers, inability to market the product we produce, among other factors, all of which could among other things, delay or prevent product release or cause our company to fail. For further risk factors see the risk factors associated with other early stage medical research and development companies filed with the SEC on Edgar.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.